Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2003Anti-Cancer Drugs

Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGraham Molineux

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Graham Molineux (2003) studied this question.

synapsesocial.com/papers/6aa0263afb5e17fb76d56299https://doi.org/10.1097/00001813-200304000-00002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer2002 · 209 citations
  2. 2Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy2000 · 268 citations
  3. 3Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs2000 · 155 citations